NCT06347497CompletedPhase 3
Zonisamide Versus Topiramate in Migraine
Safety and Efficacy of Zonisamide Versus Topiramate in Migraine
Source: ClinicalTrials.gov · Last updated 27 May 2026
Brief summary (registry, in English)
Investigators aim to compare the effect of zonisamide versus topiramate in migraine by assessing the absolute reduction in MMD in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (actual)
- First submitted
- 29 Mar 2024
- Start date
- 1 Apr 2024
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- Kafrelsheikh University
- Diseases
- Migraine
- NCT number
- NCT06347497
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 600
- From 1 Apr 2024 to the primary completion date, 1 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with valvular and ischemic heart diseases, bradycardia or heart blocks, congestive heart failure patients who received prophylactic treatment for migraine, patients with any contraindications to drugs used in the study patients with bronchial asthma, chronic obstructive pulmonary disease
Other illness
- Patients with major neurological disorders such as ( epilepsy, ischemic or hemorrhagic stroke, multiple sclerosis, mitochondrial diseases, brain tumors, and patients with essential tremors.
- patients with major systemic diseases such as malignancy, collagen, liver, and renal diseases.
Lab values
- Patients with cardiovascular diseases, such as hypertension (systolic blood pressure of more than 130 and/or diastolic blood pressure of more than 85 mm/Hg on at least three different occasions), diabetes (fasting plasma glucose level \>126 mg/dl and/or casual plasma glucose \>200 mg/dl), and/or HbA1C more than 6.5.
Who the study is looking for
- migraine patients, according to the International Classification of Headache Disorders 3rd edition,
- age from 10 to 55 years,
Age in the registry: 10 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kafr-Elsheikh University Hospital Coordinator of this site? Confirm its status | Kafr ash Shaykh | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.